Infant Bacterial Therapeutics AB (OSTO:IBT B) Buyback Yield % : -0.28 (As of May. 04, 2025)

View and export this data going back to 2016. Start your Free Trial

What is Infant Bacterial Therapeutics AB Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Infant Bacterial Therapeutics AB's current buyback yield was -0.28%.

Infant Bacterial Therapeutics AB Buyback Yield % Historical Data

The historical data trend for Infant Bacterial Therapeutics AB's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Infant Bacterial Therapeutics AB Buyback Yield % Chart

Infant Bacterial Therapeutics AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Buyback Yield %

Get a 7-Day Free Trial

-0.14

-0.01

-0.34

-8.38

-0.28

Infant Bacterial Therapeutics AB Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Buyback Yield %	Get a 7-Day Free Trial															-8.38	-9.42	-7.89	-0.45	-0.28

Competitive Comparison of Infant Bacterial Therapeutics AB's Buyback Yield %

For the Biotechnology subindustry, Infant Bacterial Therapeutics AB's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Infant Bacterial Therapeutics AB's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Infant Bacterial Therapeutics AB's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Infant Bacterial Therapeutics AB's Buyback Yield % falls into.

Save Embed

;

Save Embed

;

Infant Bacterial Therapeutics AB Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Infant Bacterial Therapeutics AB's Buyback Yield for the fiscal year that ended in Dec. 2024 is calculated as

Buyback Yield	=	Net Issuance of Stock			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	/	Market Cap
	=	- (0	+	2.013)	/	722.0456
	=	-0.28%

Infant Bacterial Therapeutics AB's annualized Buyback Yield for the quarter that ended in Dec. 2024 is calculated as

Buyback Yield	=	Net Issuance of Stock		(TTM)		/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	(TTM)^**	/	Market Cap
	=	- (0	+	2.013)		/	722.0456
	=	-0.28%

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Infant Bacterial Therapeutics AB Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Infant Bacterial Therapeutics AB's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Infant Bacterial Therapeutics AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infant Bacterial Therapeutics AB (OSTO:IBT B) » Definitions » Buyback Yield %

Comparable Companies

Traded in Other Exchanges

9IB:Germany

Address

Bryggargatan 10, Stockholm, SWE, 111 21

Website

https://www.ibtherapeutics.com

Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118 and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.

Infant Bacterial Therapeutics AB Headlines

No Headlines